Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders - Leonardi, GC; Gainor, JF; Altan, M (J Clin Oncol, 2018)
et al.